Souto EB, Macedo AS, Dias-Ferreira J, Cano A, Zieliska A, Matos CM
Bc 3 : Ly mt lng tinh cht va cho vo lng bn tay, lm nng sau p ln mt massage nh nhng dng cht c thm thu tt hn Bc 4 : Dng kem dng kha serum li khng bay hi
#AstraZeneca #GLP1 #Obesity #Type2Diabetes #ClinicalTrials #CardiometabolicHealth #PharmaInnovation Source: SPER Market ResearchViginovix To view or add a comment, sign in Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions SHANGHAI, May 29, 2026 /PRNewswire/ -- Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, today announced that new clinical data from the Phase IIb ENLIGHT study of Efsubaglutide alfa in overweight and obesity will be presented at the 2026 American Diabetes Association (ADA) Scientific Sessions, to be held from June 5 to 8, 2026, in New Orleans, Louisiana, USA
IL-1 triggers a proinflammatory response in human adipose tissues, particularly in VAT depot
Neuroendocrine modulation: effects on luteinizing hormone, growth hormone (somatotropin), and other pituitary hormones have been described
The supplement comes in easy-to-take capsules
.webp)
